co.mouthwas
Phase 2Small molecule
co.mouthwas is one of 21 small molecule programs targeting Gingivitis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Gingivitis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Cetylpyridinium Chloride
SanofiApproved
Tea Tree Oil
FFederal University of São Paulo
Approved
Triclosan
CColgate Palmolive
Phase 3
Active Comparator
ModernaPhase 2
Negative Control
GSKPhase 3
Test
RRespirent Pharmaceuticals Co Ltd.
Phase 2
Sodium Laural Sulfate
GSKPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for co.mouthwas. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Baghdad